What is Tesamorelin?
Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH). Sold under the brand name Egrifta, it is described in labeling as acting through the pituitary growth-hormone axis.1
Unlike most peptides in this library, tesamorelin is an FDA-approved drug with a specific labeled indication: reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy.1 That approval defines a documented evidence base for the labeled use; uses beyond that indication are off-label.
Benefits & what it’s studied for
Per the FDA label and supporting visceral-fat trials for Egrifta, tesamorelin was studied for excess visceral abdominal fat in the approved HIV-associated lipodystrophy population.1
Labeling and reviews describe increases in endogenous GH and IGF-1 as part of the pharmacologic pathway; clinical meaning outside the labeled use is less established.2
Because visceral fat is metabolically active, tesamorelin appears in broader metabolic research literature — largely early-stage outside the labeled indication.2
How does Tesamorelin work?
Tesamorelin is a GHRH analog: labeling describes it as stimulating pituitary release of growth hormone, with downstream effects on the GH/IGF-1 axis. In the approved setting, that pathway was studied in relation to visceral adipose tissue.1 Direct growth-hormone injection is a different product class with a different risk profile; this page does not compare them as treatment choices.
Dosing & administration
As an FDA-approved prescription product, tesamorelin has a label-specified administration schedule and monitoring requirements set by the prescribing information — not by this website. Labeling discusses adverse reactions that can include injection-site reactions and effects on glucose tolerance, among other items.1 Appropriateness depends on individual clinical factors listed in the label (including certain malignancies and pregnancy-related contraindications).
This is educational, not medical advice. Nothing on this page is a protocol, prescription, or instruction for use. Candidacy, product selection, and monitoring — if any — are determined only by a licensed clinician.
Legality & status
Tesamorelin is an FDA-approved prescription drug for its specific labeled indication. Any use beyond that indication is off-label and a clinical decision; compounded versions, where they exist, are regulated differently from the branded product. Access, if any, is through a licensed clinician and a valid prescription. See how legitimate peptide therapy is described on this site.
Thinking about Tesamorelin?
Talk to a licensed provider who can tell you if it fits your goals — and build a safe protocol.
Research & references
- 1Egrifta (tesamorelin) FDA prescribing information & visceral-fat trials. FDA / DailyMed link to be finalized. link pending
- 2Tesamorelin, GH/IGF-1 axis, and metabolic effects — review. Citation to be finalized. link pending
Reference links are illustrative placeholders — replace with verified PubMed/journal URLs before publishing.
Frequently asked questions
What is tesamorelin used for?+
Tesamorelin (Egrifta) is FDA-approved to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Research and off-label discussion also appear in the broader visceral-fat literature; those uses are clinical decisions outside the labeled indication.
Is tesamorelin FDA-approved?+
Yes — for a specific indication: reducing visceral abdominal fat in people with HIV-associated lipodystrophy. Other uses are off-label.
How is tesamorelin different from sermorelin?+
Both are GHRH-related peptides. Tesamorelin is a stabilized analog with an FDA-approved visceral-fat indication (Egrifta). Sermorelin is the shorter GHRH 1-29 fragment and does not share that same approved indication.
Does tesamorelin cause weight loss?+
The labeled evidence concerns visceral abdominal fat in the approved population, not general scale-weight loss of the kind studied for GLP-1 medicines. Individual outcomes vary and are clinical questions.
What does the label say about safety?+
As an approved drug, tesamorelin has a defined prescribing-information safety section (including glucose-related and other warnings). It is prescription-only; suitability is a clinician decision against the label.